CA2229078C - Pharmaceutical composition containing il-10 - Google Patents

Pharmaceutical composition containing il-10 Download PDF

Info

Publication number
CA2229078C
CA2229078C CA2229078A CA2229078A CA2229078C CA 2229078 C CA2229078 C CA 2229078C CA 2229078 A CA2229078 A CA 2229078A CA 2229078 A CA2229078 A CA 2229078A CA 2229078 C CA2229078 C CA 2229078C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
healing
wound
wounds
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2229078A
Other languages
English (en)
French (fr)
Other versions
CA2229078A1 (en
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of CA2229078A1 publication Critical patent/CA2229078A1/en
Application granted granted Critical
Publication of CA2229078C publication Critical patent/CA2229078C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
CA2229078A 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10 Expired - Fee Related CA2229078C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
GB9516287.1 1995-08-09
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (2)

Publication Number Publication Date
CA2229078A1 CA2229078A1 (en) 1997-02-20
CA2229078C true CA2229078C (en) 2010-04-20

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2229078A Expired - Fee Related CA2229078C (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0941108T3 (da) * 1996-12-04 2002-11-18 Renovo Ltd Sårheling og behandling af fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
AU6951300A (en) * 1999-09-08 2001-04-10 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
WO2009120799A2 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
ES2957546T3 (es) 2008-12-17 2024-01-22 Merck Sharp & Dohme Producción de mono- y di-PEG-IL10; y usos
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (en) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Membrane structure coated with low pI protein and methods of making and using
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
ES2124702T3 (es) 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
JPH0747545B2 (ja) * 1991-01-10 1995-05-24 シェリング・コーポレーション 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993004164A1 (en) 1991-08-26 1993-03-04 THE STATE OF OREGON acting by and through THE STATE OF BOARD OF HIGHER EDUCATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
AU7043694A (en) * 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
IL110413A0 (en) 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
EP0968723B1 (en) * 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor
CA2205572A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
AU719089B2 (en) 2000-05-04
US7052684B2 (en) 2006-05-30
EP0871473A1 (en) 1998-10-21
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
PT871473E (pt) 2003-03-31
CA2229078A1 (en) 1997-02-20
GB2304047A (en) 1997-03-12
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
DK0871473T3 (da) 2003-04-14
JP4050317B2 (ja) 2008-02-20
US6387364B1 (en) 2002-05-14
JPH11510505A (ja) 1999-09-14
ATE229814T1 (de) 2003-01-15
DE69625516T2 (de) 2003-09-25
GB9516287D0 (en) 1995-10-11
WO1997005894A1 (en) 1997-02-20
DE69625516D1 (de) 2003-01-30
ES2187665T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
EP0871473B1 (en) Use of il-10 for wound healing with reduced scarring
DE69424576T2 (de) Biologisch aktive tgf-beta1 und tgf-beta2 peptide
ES2426420T3 (es) Péptidos de queratina bioactivos
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
EP0968723B1 (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
Yang et al. Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure
JP4616291B2 (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
US5202118A (en) Method for promoting wound healing using IL-1
EP1719522B1 (en) Medicinal composition comprising TCF-II
DE69836315T2 (de) Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
ES2227601T5 (es) Utilizacion de betaglicano para reducir la cicatrizacion.
DE69209051T2 (de) Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren
US20080031879A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
WO2000004873A1 (en) Dermatological compositions for the treatment of scars
DE69916022T2 (de) Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs
WO1995007710A1 (en) Remedy for wound
JPH0656692A (ja) Ｔｃｆ−ｉｉを有効成分とする創傷治療剤
WO2000057902A1 (en) Method and pharmaceutical composition for wound healing
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
JPH08283174A (ja) 脊髄損傷後の神経障害に対する治療剤
KR20120071736A (ko) 애기뿔소똥구리에서 분리한 펩타이드를 유효성분으로 포함하는 창상 치료용 또는 항균용 조성물
Kim Effect of Anti-TGFß1 and Pycnogenol® on Scar Formation in Rats

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150810